Top

Published in:

01-02-2011 | Preclinical study

Interactions between breast cancer cells and bone marrow derived cells in vitro define a role for osteopontin in affecting breast cancer cell migration

Authors: Konstantin Koro, Stephen Parkin, Brant Pohorelic, An-Dao Yang, Aru Narendran, Cay Egan, Anthony Magliocco

Published in: Breast Cancer Research and Treatment | Issue 1/2011

Abstract

The preferential metastasis of breast cancer cells to bone is a complex set of events including homing and preferential growth which may include unique factors produced by bone cells in the immediate microenvironment. In this study, we evaluated the suitability of bone cells derived from orthoplastic surgeries for use in an in vitro co-culture system representing a model of the bone microenvironment. Using a limiting dilution assay we determined the relative survival and proliferation potentials of breast cancer cell lines co-cultured on bone-derived cells or on Hs68 fibroblasts. The comparison of bone and skin fibroblastic substrata indicates that MCF-7 cells preferentially survive and grow in a bone microenvironment (P < 0.001). Overall, we show that bone-derived cells enhance survival, proliferation, and migration of breast cancer cells, where migration is in part mediated by bone cell-produced osteopontin. Our in vitro co-culture model system provides a robust cost-effective method to study the various factors that mediate cancer/bone-derived cell interactions.

Available only for authorised users

Coleman RE, Rubens RD (1987) The clinical course of bone metastases from breast cancer. Br J Cancer 55:61–66CrossRefPubMedPubMedCentral

Fokas E, Engenhart-Cabillic R, Daniilidis K, Rose F, An HX (2007) Metastasis: the seed and soil theory gains identity. Cancer Metastasis Rev 26:705–715CrossRefPubMed

Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584–593CrossRefPubMed

Rabbani SA, Mazar AP (2007) Evaluating distant metastases in breast cancer: from biology to outcomes. Cancer Metastasis Rev 26:663–674CrossRefPubMed

Paget S (1889) The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev 8:98–101

Kaplan RN, Psaila B, Lyden D (2006) Bone marrow cells in the ‘pre-metastatic niche’: within bone and beyond. Cancer Metastasis Rev 25:521–529CrossRefPubMed

Tuck AB, Chambers AF (2001) The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia 6:419–429CrossRefPubMed

Cook AC et al (2005) Osteopontin induces multiple changes in gene expression that reflect the six “hallmarks of cancer” in a model of breast cancer progression. Mol Carcinog 43:225–236CrossRefPubMed

Coppola D et al (2004) Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10:184–190CrossRefPubMed

10.

Rudland PS et al (2002) Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 62:3417–3427PubMed

11.

Fedarko NS, Jain A, Karadag A (2001) Van Eman, M.R. & Fisher, L.W. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7:4060–4066PubMed

12.

Tuck AB, Elliott BE, Hota C, Tremblay E, Chambers AF (2000) Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J Cell Biochem 78:465–475CrossRefPubMed

13.

Singhal H et al (1997) Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 3:605–611PubMed

14.

Tuck AB et al (1999) Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 18:4237–4246CrossRefPubMed

15.

Furger KA, Menon RK, Tuck AB, Bramwell VH, Chambers AF (2001) The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 1:621–632CrossRefPubMed

16.

Chambers AF (2009) MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? Cancer Res 69:5292–5293CrossRefPubMed

17.

Christgen M, Lehmann U (2007) MDA-MB-435: the questionable use of a melanoma cell line as a model for human breast cancer is ongoing. Cancer Biol Ther 6:1355–1357CrossRefPubMed

18.

Ellison G et al (2002) Further evidence to support the melanocytic origin of MDA-MB-435. Mol Pathol 55:294–299CrossRefPubMedPubMedCentral

19.

Lacroix M (2009) MDA-MB-435 cells are from melanoma, not from breast cancer. Cancer Chemother Pharmacol 63:567CrossRefPubMed

20.

Rae JM, Creighton CJ, Meck JM, Haddad BR, Johnson MD (2007) MDA-MB-435 cells are derived from M14 melanoma cells—a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat 104:13–19CrossRefPubMed

21.

Ross DT et al (2000) Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24:227–235CrossRefPubMed

22.

Sellappan S et al (2004) Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. Cancer Res 64:3479–3485CrossRefPubMed

23.

Rastaldi MP et al (2002) Epithelial-mesenchymal transition of tubular epithelial cells in human renal biopsies. Kidney Int 62:137–146CrossRefPubMed

24.

Davila RM, Crouch EC (1993) Role of mesothelial and submesothelial stromal cells in matrix remodeling following pleural injury. Am J Pathol 142:547–555PubMedPubMedCentral

25.

Lefkovits I, Waldmann H (1999) Limiting dilution analysis of cells of the immune system. Oxford University Press, New York

26.

Laemmli K (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685CrossRefPubMed

27.

Wagner W, Ho AD (2007) Mesenchymal stem cell preparations—comparing apples and oranges. Stem Cell Rev 3:239–248CrossRefPubMed

28.

Wagner W et al (2007) Molecular and secretory profiles of human mesenchymal stromal cells and their abilities to maintain primitive hematopoietic progenitors. Stem Cells 25:2638–2647CrossRefPubMed

29.

Kapoor P, Suva LJ, Welch DR, Donahue HJ (2008) Osteoprotegrin and the bone homing and colonization potential of breast cancer cells. J Cell Biochem 103:30–41CrossRefPubMed

30.

Mercer RR, Mastro AM (2005) Cytokines secreted by bone-metastatic breast cancer cells alter the expression pattern of f-actin and reduce focal adhesion plaques in osteoblasts through PI3 K. Exp Cell Res 310:270–281CrossRefPubMed

31.

Mazzali M et al (2002) Osteopontin—a molecule for all seasons. QJM 95:3–13CrossRefPubMed

32.

Denhardt DT, Guo X (1993) Osteopontin: a protein with diverse functions. FASEB J 7:1475–1482PubMed

33.

Rittling SR, Chambers AF (2004) Role of osteopontin in tumour progression. Br J Cancer 90:1877–1881CrossRefPubMedPubMedCentral

34.

Wai PY, Kuo PC (2004) The role of Osteopontin in tumor metastasis. J Surg Res 121:228–241CrossRefPubMed

35.

Giachelli CM, Steitz S (2000) Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol 19:615–622CrossRefPubMed

36.

Frolke JP et al (2004) Viable osteoblastic potential of cortical reamings from intramedullary nailing. J Orthop Res 22:1271–1275CrossRefPubMed

37.

Kaur D, Berger P, Duffy SM, Brightling CE, Bradding P (2005) Co-cultivation of mast cells and Fc epsilon RI alpha + dendritic-like cells from human hip bone marrow. Clin Exp Allergy 35:226–233CrossRefPubMed

38.

Tydings JD, Martino LJ, Kircher M, Alfred RH, Lozman J (1987) Viability of intramedullary canal bone reamings for continued calcification. Am J Surg 153:306–309CrossRefPubMed

39.

Lodie TA et al (2002) Systematic analysis of reportedly distinct populations of multipotent bone marrow-derived stem cells reveals a lack of distinction. Tissue Eng 8:739–751CrossRefPubMed

40.

Hughes L, Malone C, Chumsri S, Burger AM, McDonnell S (2008) Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity. Clin Exp Metastasis 25:549–557CrossRefPubMed

41.

Plopper GE, Domanico SZ, Cirulli V, Kiosses WB, Quaranta V (1998) Migration of breast epithelial cells on Laminin-5: differential role of integrins in normal and transformed cell types. Breast Cancer Res Treat 51:57–69CrossRefPubMed

42.

Zhang X et al (2004) Motility response to insulin-like growth factor-I (IGF-I) in MCF-7 cells is associated with IRS-2 activation and integrin expression. Breast Cancer Res Treat 83:161–170CrossRefPubMed

43.

Rodrigues LR, Teixeira JA, Schmitt FL, Paulsson M, Lindmark-Mansson H (2007) The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev 16:1087–1097CrossRefPubMed

44.

Noti JD (2000) Adherence to osteopontin via alphavbeta3 suppresses phorbol ester-mediated apoptosis in MCF-7 breast cancer cells that overexpress protein kinase C-alpha. Int J Oncol 17:1237–1243PubMed

45.

Tanabe KK, Nishi T, Saya H (1993) Novel variants of CD44 arising from alternative splicing: changes in the CD44 alternative splicing pattern of MCF-7 breast carcinoma cells treated with hyaluronidase. Mol Carcinog 7:212–220CrossRefPubMed

46.

He B, Mirza M, Weber GF (2005) An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene 25:2192–2202CrossRef

47.

Adwan H, Bauerle TJ, Berger MR (2004) Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells. Cancer Gene Ther 11:109–120CrossRefPubMed

48.

Bautista DS, Xuan JW, Hota C, Chambers AF, Harris JF (1994) Inhibition of Arg-Gly-Asp (RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin. J Biol Chem 269:23280–23285PubMed

49.

Denhardt DT, Noda M (1998) Osteopontin expression and function: role in bone remodeling. J Cell Biochem Suppl 30–31:92–102CrossRefPubMed

Title: Interactions between breast cancer cells and bone marrow derived cells in vitro define a role for osteopontin in affecting breast cancer cell migration
Authors: Konstantin Koro
Stephen Parkin
Brant Pohorelic
An-Dao Yang
Aru Narendran
Cay Egan
Anthony Magliocco
Publication date: 01-02-2011
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-0889-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

A systematic review of the relationship between polymorphic sites in the estrogen receptor-beta (ESR2) gene and breast cancer risk

Body weight and risk of breast cancer in BRCA1/2 mutation carriers

Effects of breast cancer surgery and surgical side effects on body image over time

Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients

Erratum to: Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors

Effects of breast cancer surgery and surgical side effects on body image over time

Keynote webinar | Spotlight on antibody–drug conjugates in cancer